Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019383 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019383: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019383 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019383, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving the vaccine with interleukin-2 or sargramostim may help kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peptide vaccine with or without adjuvant interleukin-2 or sargramostim in treating patients who have recurrent or refractory metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL tyrosinase-related protein-1
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-01 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00019383 record still lists
NCT00019383 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which aldesleukin is the first listed.
NCT00019383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019383 about?
NCT00019383 is a clinical study titled "Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving the vaccine with interleukin-2 or sargramostim may help kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peptide vaccine with or without adjuvant interleukin-2 or sargramostim in t...
What is the current status of trial NCT00019383?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-01. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00019383?
The interventions under investigation include: aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), tyrosinase-related protein-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019383?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia